Abstract
Objective: To calculate per-case hospital costs for patients with cystic fibrosis under routine conditions from a healthcare provider’s perspective; identify the impact of different cost categories; investigate whether cases with cystic fibrosis can be grouped into homogenous cost groups according to defined severity levels; and determine the value of specific factors as predictors of hospital cost variations.
Methods: All data were collected from cases (n = 131) admitted to an inpatient cystic fibrosis unit under routine conditions during a period of 6 months in 2004. All costs were calculated for the year 2004 and divided into categories with high and low impact on variation in hospitalisation costs between patients. Staff costs for patient care, laboratory costs and drug costs were defined as categories with high impact, thus the individual resource utilisation for each case was measured. Cost categories that were classified as having a low impact were measured as overhead costs.
Cases were classified according to two different severity models; within each model, patients were classified according to three severity levels. The diagnosis-related model classifies patients with pulmonary hypertension and global respiratory insufficiency as having severe disease, patients with Pseudomonas aeruginosa as having moderate disease, and patients with no colonisation of the lungs as having mild disease. The lung-function-related model differentiates patients as having mild, moderate and severe disease when patients have forced expiratory volumes in 1 second (FEV1) that are ≥70%, between ≥40% and <70%, and <40%, respectively.
Analysis of variance tests were performed to investigate the differences of mean costs between the groups. Ordinary least squares regression analysis was used to determine predictors for cost variation.
Results: The mean total costs per case were €7326. Almost one-third of the total mean costs were attributable to drug costs (28% of total costs), while shares of staff costs for patient care and laboratory costs (both 9% of total costs) were relatively small. Most of the difference in costs between severity levels was attributable to the variation in overhead costs and drug costs. For both severity models differences in mean total costs of mild and severe cases were statistically significant (p < 0.01 and p < 0.05, respectively) when compared with the mean costs of non-mild and non-severe cases. However, in moderate cases, significant differences compared with cases that were not of moderate severity were only seen for certain cost categories. In the multiple regression model the variables ‘diagnosis-related severity’ and ‘FEV1’ explained 31% of the variance of ‘Ln (total costs per case)’ between severity levels (p ≤ 0.01).
Conclusion: This study shows that to a large extent hospitalisation costs for patients with cystic fibrosis vary according to the severity of their disease; drug costs play a major role in these differences. In the light of this variation it seems plausible to create separate reimbursement rates for two or three severity groups. Diagnoses as well as FEV1 seem suitable criteria for such a classification.
Similar content being viewed by others
References
Cystic Fibrosis Foundation. Patient registry 2003 annual data report. Bethesda (MD): Cystic Fibrosis Foundation, 2004
Lees CM, Smyth RL. The current management of cystic fibrosis. Int J Clin Pract 2000; 54: 171–179
Hoiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2000; 2: 451–462
FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1–9
Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999; 19: 1159–1166
Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003; 2: 84–90
Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organisation. Pediatrics 1999; 103: e72
Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. J Pediatr 1994; 124: 177–192
Robson M, Abbot J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684–689
Wildhagen MF, Verheij JB, Hilderink HB, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1. Thorax 1996a; 51: 298–301
Wildhagen MF, Verheij JB, Verzikl JG, et al. The nonhospital costs of patients with CF in The Netherlands: results of a questionnaire. Eur Respir J 1996b; 9: 2215–2219
Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22: 857–876
Krauth C, Jalivand N, Welte T, et al. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003; 21: 1001–1024
Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 1996; 143: 1007–117
Kerem E, Reisman J, Corey A, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187–1191
Gujarati DN. Basic econometrics. Singapore: McGraw Hill, 2002
InEK (Institute for Hospital Reimbursement). Report browser for G-DRG version 2005 [online]. Available from URL: http:// www.g-drg.de/ [Accessed 2006 Mar 6]
Ireys HT, Anderson GF, Shaffert TJ, et al. Expenditures for care of children with chronic illnesses enrolled in the Washington State Medicaid Program, fiscal year 1993. Pediatrics 1997, 204
Pauly MV. The economics of cystic fibrosis. In: Lloyd-Still JD, editor. Textbook of cystic fibrosis. Boston (MA): John Wright PSG Inc., 1983: 465–476
US Congress Office of Technology Assessment. Cystic fibrosis and DNA tests: implications of carrier screening. Washington, DC: US Government Printing Office, 1992
Zentrum für Qualitätssicherung. Qualitätssicherung Mukoviszidose. Hannover: Zentrum für Qualitätssicherung, 2004
Acknowledgements
This work was planned by Jonas Schreyögg, Helge Hollmeyer, Miriam Blumel and Doris Staab, and was written and the final version approved by all the authors. There was no external funding for this study, and none of the authors has any potential conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schreyögg, J., Hollmeyer, H., Bluemel, M. et al. Hospitalisation Costs of Cystic Fibrosis. Pharmacoeconomics 24, 999–1009 (2006). https://doi.org/10.2165/00019053-200624100-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200624100-00007